Skip to main content
Clinical Trials/IRCT20180620040164N67
IRCT20180620040164N67Not yet recruitingUnknown

Comparative bioequivalence study of Metformin 1000 mg E.R. Tablet of Dorsa Pharmaceutical Co and Merck

Dorsa Pharmaceutical Co.0 sites24 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Unknown
Status
Not yet recruiting
Sponsor
Enrollment
24

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 45 years (—)
Sex
Male

Inclusion Criteria

  • Healthy subjects (male) between 18 – 45 years of age and Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m2.
  • Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.

Exclusion Criteria

  • History of known sensitivity to the tested products
  • Associated acute or chronic infections
  • Blood pressure in standing position and after 5 minutes of rest, systole less than 90 or more than 140 mm Hg and diastole less than 50 or more than 90 mm Hg.
  • Heart rate less than 50 or more than 90 beats per minute
  • Abnormalities in ECG include (PR > 210 msec, QRS complex > 120 msec, QTcF > 430 msec)
  • Smoking more than 10 cigarettes a day
  • Loss of more than 500 ml of blood in less than 7 days.

Investigators

Sponsor
Dorsa Pharmaceutical Co.

Similar Trials